Medindia

X

SuperGen to Present at BIO CEO & Investor Conference on February 10, 2009

Wednesday, February 4, 2009 General News J E 4
Advertisement
DUBLIN, Calif., Feb. 3 SuperGen, Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced that James S. Manuso, Ph.D., President and Chief Executive Officer, is scheduled to present at the BIO CEO & Investor Conference on February 10, 2009 at the Waldorf-Astoria in New York.



SuperGen's presentation at the BIO CEO & Investor Conference is scheduled to begin at 11:30 a.m. ET. A live webcast of the presentation will be available on the investor relations section of the Company's Web site at www.supergen.com. The webcast will be archived for 90 days.



About SuperGen

Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical company dedicated to the discovery and development of novel cancer therapies. SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For more information about SuperGen, please visit http://www.supergen.com.



Forward-Looking Statements

This news release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that may cause actual results to differ materially from the results discussed in these statements. Factors that might cause the company's results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, our ability to discover, develop and move target compounds into clinical development and other risks and uncertainties detailed from time to time in the company's filings with the Securities and Exchange Commission including its most recently filed Form 10-Q and 10-K. SuperGen, Inc. undertakes no duty to update any of these forward-looking statements to conform them to actual results.



Contacts: Timothy L. Enns SuperGen, Inc. SVP, Corporate Communications & Business Development Tel: (925) 560-2810 E-mail: tenns@supergen.com Susanna Chau SuperGen, Inc. Investor Relations Manager Tel: (925) 560-2845 E-mail: schau@supergen.com

SOURCE SuperGen, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Soy May Reduce Risk of Colorectal Cancer
S
Human Resource Executive(R) 7th Annual NY HR Week(...